Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937859 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TDP1CYP3A4LMNAHTT | |
| SCHEMBL3675118 | 0.88 | ALDH1A1 (0.48) | ALDH1A1TDP1CYP3A4LMNAHTT | |
| SCHEMBL4458565 | 0.84 | MAPT (0.51) | ALDH1A1LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL29937396 | 0.84 | MAPT (0.51) | ALDH1A1LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL77799 | 0.84 | ALDH1A1 (0.54) | ALDH1A1TDP1LMNAHTTSMN1; SMN2 | |
| SCHEMBL2942752 | 0.82 | SMN1; SMN2 (0.43) | ALDH1A1TDP1CYP3A4LMNAHTT | |
| SCHEMBL5375868 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4LMNAHTT | |
| SCHEMBL5624620 | 0.81 | SLC6A9 (0.46) | ALDH1A1TDP1HTTSMN1; SMN2MAPT | |
| SCHEMBL27656428 | 0.81 | CTSB (0.45) | ALDH1A1TDP1CYP3A4LMNAHTT | |
| SCHEMBL5628031 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNAHTTSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215816-B | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-115215816-A | Synthesis method of lactam compound | 普济生物科技（台州）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | DORSCH DIETER | 2010-08-19 | — | — | US | disclosed |
| US-7687624-B2 | Process for the production of N-arylmorpholinones | MERCK PATENT GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
| WO-2007025940-A1 | SUBSTITUTED BIARYLS AND THEIR USE AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-08 | — | — | WO | disclosed |
| EP-1654240-B1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | MERCK PATENT GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1654240-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016899-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | CYP1A1, CYP1B1, OPRM1 | ALDH1A1 264/4885TDP1 2702/4885CYP3A4 25/4885 |
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | CYP11B2, CYP3A43, CYP11B1 | ALDH1A1 517/4885TDP1 2505/4885CYP3A4 51/4885 |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | PLAT, PCSK9, SERPINE1 | ALDH1A1 2931/4885TDP1 874/4885CYP3A4 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.